---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-104575"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2024-09-09T23:59:59+00:00"
generated_at: "2026-05-31T05:55:30.289570+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics Publishes Phase 1 Abstract for PRT3789 SMARCA2 Degrader at ESMO 2024

## Summary
- Abstract details first clinical data for PRT3789, a first-in-class IV SMARCA2 degrader in SMARCA4-mutated advanced solid tumors.
- As of March 7, 2024, 40 patients enrolled across 6 dose levels (24-212 mg); no DLTs or study-drug-related SAEs reported.
- Dose-dependent decreases in SMARCA2 levels observed; RECIST partial responses and tumor shrinkage noted in heavily pretreated NSCLC and esophageal cancer.
- Company will host investor webcast on September 13, 2024 at 12:00 PM EST following oral presentation at ESMO Congress.

## SEC filing metadata
- accession: 0000950170-24-104575
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2024-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017024104575/0000950170-24-104575-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017024104575/prld-20240909.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-104575
- JSON: https://secwatch.observer/filing/0000950170-24-104575.json
- Plain text: https://secwatch.observer/filing/0000950170-24-104575.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.